{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:08:26Z","timestamp":1793815706072,"version":"4.6.1"},"reference-count":32,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100017478","name":"Usona Institute","doi-asserted-by":"publisher","award":["Psilocybin for treatment of OCD"],"award-info":[{"award-number":["Psilocybin for treatment of OCD"]}],"id":[{"id":"10.13039\/100017478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Current treatments for obsessive\u2013compulsive disorder (OCD), including serotonin reuptake inhibitors and cognitive-behavioral therapy, are often insufficient. Psilocybin, a 5HT2a agonist psychedelic, has shown promise for treating OCD, but rigorous evidence is still needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>This randomized clinical trial evaluated safety, tolerability, and benefit of multiple psilocybin doses in OCD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Fifteen participants were randomized to receive 4 weekly sessions of high-dose (300\u2009\u00b5g\/kg), low-dose (100\u2009\u00b5g\/kg) psilocybin, or active placebo (lorazepam) in a double-blind Phase 1 (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20095\u2009per condition), followed by four additional high-dose sessions (single-blind Phase 2). OCD severity was assessed with the Yale-Brown Obsessive Compulsive Scale (YBOCS) following each session, and prospectively for 6 months. Safety was evaluated via adverse event systematic assessment, suicide severity rating, and psychosis screening.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Psilocybin was generally well-tolerated, with no serious adverse events, or psychotic symptoms, and no significant changes in suicide severity scores. Psilocybin but not placebo significantly reduced YBOCS scores. At the end of 8-week treatment, after participants had received at least four high doses of psilocybin, 73.3% were responders (\u2a7e35% reduction in YBOCS scores), with 40% in remission. These effects diminished but remained substantial at 6\u2009months. Post hoc analysis of cumulative dosing correlated with YBOCS score reductions at the end of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Administration of up to eight doses of psilocybin in a clinical research setting appears to be safe and potentially effective for patients with OCD. Larger trials are needed to further support efficacy and refine treatment protocols.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov ID NCT03300947.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811261424214","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T01:01:21Z","timestamp":1773450081000},"page":"837-849","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive\u2013compulsive disorder"],"prefix":"10.1177","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0700-6508","authenticated-orcid":false,"given":"Francisco A.","family":"Moreno","sequence":"first","affiliation":[{"name":"Department of Psychiatry, College of Medicine - Tucson, University of Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1659-2168","authenticated-orcid":false,"given":"Katja E.","family":"Allen","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, College of Medicine - Tucson, University of Arizona, USA"},{"name":"Department of Psychology, College of Science, University of Arizona, Tucson, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9485-0724","authenticated-orcid":false,"given":"Christopher B.","family":"Wiegand","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, College of Medicine - Tucson, University of Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5308-8925","authenticated-orcid":false,"given":"Rajan","family":"Dunne","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, College of Medicine - Tucson, University of Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6147-6240","authenticated-orcid":false,"given":"James I.","family":"Prickett","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, College of Medicine - Tucson, University of Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5649-181X","authenticated-orcid":false,"given":"Brian","family":"Bayze","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, College of Medicine - Tucson, University of Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3417-6720","authenticated-orcid":false,"given":"John J. B.","family":"Allen","sequence":"additional","affiliation":[{"name":"Department of Psychology, College of Science, University of Arizona, Tucson, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811231224217"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2020.116980"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2487"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-39812-0"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.118.017160"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2014.00020"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2025.1726818"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01744-z"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1659-20.2020"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2021_279"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811241237870"},{"key":"e_1_3_3_14_1","volume-title":"Structured Clinical Interview for DSM-5, Research Version","author":"First MB","year":"2015","unstructured":"First MB, Williams JBW, Karg RS, et al. (2015) Structured Clinical Interview for DSM-5, Research Version. American Psychiatric Publishing."},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1989.01810110054008"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003664"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocrd.2024.100873"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e12135"},{"issue":"2","key":"e_1_3_3_19_1","first-page":"343","article-title":"SAFTEE: A technique for the systematic assessment of side effects in clinical trials","volume":"22","author":"Levine J","year":"1986","unstructured":"Levine J, Schooler NR (1986) SAFTEE: A technique for the systematic assessment of side effects in clinical trials. Psychopharmacology Bulletin 22(2): 343\u2013381.","journal-title":"Psychopharmacology Bulletin"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20299"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.154.7.1037b"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n1110"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpsc.2018.03.009"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2018.11.010"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2005.11.028"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2025.152619"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10111704"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tics.2011.11.009"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2024.115880"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-8-18"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1037\/0033-2909.86.2.420"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07624-5"},{"key":"e_1_3_3_33_1","volume-title":"Drugs of Abuse, A DEA Resource Guide","author":"U.S. Department of Justice Drug Enforcement Administration","year":"2020","unstructured":"U.S. Department of Justice Drug Enforcement Administration (2020) Drugs of Abuse, A DEA Resource Guide, 2020 edn. Drug Enforcement Administration, U.S. Department of Justice.","edition":"2020"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261424214","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811261424214","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261424214","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T05:17:18Z","timestamp":1782710238000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811261424214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1177\/02698811261424214"],"URL":"https:\/\/doi.org\/10.1177\/02698811261424214","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]}}}